NEW YORK, NY / ACCESSWIRE / August 26, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Bayer Aktiengesellschaft (OTCMKT:BAYRY)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/bayer-aktiengesellschaft-loss-submission-form?prid=8837&wire=1
Lead Plaintiff Deadline: September 14, 2020
Lawsuit on behalf of all persons or entities that purchased or otherwise acquired Bayer American Depositary Receipts between May 23, 2016 and March 19, 2019.
Allegations against BAYRY include that: 1) following its acquisition of Monsanto Company, Bayer could be at risk of suffering billions of dollars in judgments and reputational damage if the lawsuits brought against Monsanto alleging that exposure to its glyphosate-based Roundup product caused cancer were successful, 2) a result, Defendants' positive statements about the prospects of the Monsanto acquisition and the benefits it would create for Bayer's business were materially false and/or misleading and/or lacked a reasonable basis.
Baidu, Inc. (NASDAQ:BIDU)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/baidu-inc-loss-submission-form-2?prid=8837&wire=1
Lead Plaintiff Deadline: October 19, 2020
Class Period: April 8, 2016 - August 13, 2020
Allegations against BIDU include that: (1) Baidu misrepresented the financial and business condition of iQIYI; (2) iQIYI had inadequate controls; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Vaxart, Inc. (NASDAQ:VXRT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/vaxart-inc-loss-submission-form-2?prid=8837&wire=1
Lead Plaintiff Deadline: October 23, 2020
Class Period: June 25, 2020 - July 25, 2020
Allegations against VXRT include that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong